Literature DB >> 25223521

Alteration of cell-cell and cell-matrix adhesion in urothelial cells: an oncogenic mechanism for mutant FGFR3.

Erica di Martino1, Gavin Kelly2, Jo-An Roulson3, Margaret A Knowles4.   

Abstract

UNLABELLED: Activating mutations of FGFR3 are a common and early event in bladder cancer. Ectopic expression of mutant FGFR3 in normal urothelial cells has both pro-proliferative and antiapoptotic effects at confluence, suggesting that mutant cells are insensitive to cell-cell contact inhibition. Herein, detailed analysis revealed that these cells have reduced cell-cell adhesion, with large intercellular spaces observable at confluence, and diminished cell-substrate adhesion to collagen IV, collagen I, and fibronectin. These phenotypic alterations are accompanied by changes in the expression of genes involved in cell adhesion and extracellular matrix remodeling. Silencing of endogenous mutant FGFR3 in bladder cancer cells induced converse changes in transcript levels of CDH16, PLAU, MMP10, EPCAM, TNC, and HAS3, confirming them as downstream gene targets of mutant FGFR3. Overexpression of EPCAM, HAS3, and MMP10 transcripts was found in a large fraction of primary bladder tumors analyzed, supporting their key role in bladder tumorigenesis in vivo. However, no correlation was found between their protein and/or mRNA expression and FGFR3 mutation status in tumor specimens, indicating that these genes may be targeted by several converging oncogenic pathways. Overall, these results indicate that mutant FGFR3 favors the development and progression of premalignant bladder lesions by altering key genes regulating the cell-cell and cell-matrix adhesive properties of urothelial cells. IMPLICATIONS: The ability of mutant FGFR3 to drive transcriptional expression profiles involved in tumor cell adhesion suggests a mechanism for expansion of premalignant urothelial lesions. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25223521     DOI: 10.1158/1541-7786.MCR-14-0022

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  7 in total

1.  Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis.

Authors:  Sunny Guin; Yuanbin Ru; Neeraj Agarwal; Carolyn R Lew; Charles Owens; Giacomo P Comi; Dan Theodorescu
Journal:  Clin Cancer Res       Date:  2015-10-21       Impact factor: 12.531

Review 2.  A place for precision medicine in bladder cancer: targeting the FGFRs.

Authors:  Erica di Martino; Darren C Tomlinson; Sarah V Williams; Margaret A Knowles
Journal:  Future Oncol       Date:  2016-07-06       Impact factor: 3.404

3.  ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer.

Authors:  Erica di Martino; Olivia Alder; Carolyn D Hurst; Margaret A Knowles
Journal:  Sci Rep       Date:  2019-04-05       Impact factor: 4.379

4.  HS2ST1-dependent signaling pathways determine breast cancer cell viability, matrix interactions, and invasive behavior.

Authors:  Archana Vijaya Kumar; Stéphane Brézillon; Valérie Untereiner; Ganesh Dhruvananda Sockalingum; Sampath Kumar Katakam; Hossam Taha Mohamed; Björn Kemper; Burkhard Greve; Benedikt Mohr; Sherif Abdelaziz Ibrahim; Francisco M Goycoolea; Ludwig Kiesel; Mauro S G Pavão; Juliana M Motta; Martin Götte
Journal:  Cancer Sci       Date:  2020-07-09       Impact factor: 6.716

5.  Correlation Between Circulating Tumor Cell DNA Genomic Alterations and Mesenchymal CTCs or CTC-Associated White Blood Cell Clusters in Hepatocellular Carcinoma.

Authors:  Chunming Wang; Qiong Luo; Wenbin Huang; Cheng Zhang; Hangyu Liao; Kunling Chen; MingXin Pan
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

6.  Whole genome and transcriptome sequencing of matched primary and peritoneal metastatic gastric carcinoma.

Authors:  J Zhang; J Y Huang; Y N Chen; F Yuan; H Zhang; F H Yan; M J Wang; G Wang; M Su; G Lu; Y Huang; H Dai; J Ji; J Zhang; J N Zhang; Y N Jiang; S J Chen; Z G Zhu; Y Y Yu
Journal:  Sci Rep       Date:  2015-09-02       Impact factor: 4.379

7.  FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation.

Authors:  Mona Foth; Nur Faezah Binti Ismail; Jeng Sum Charmaine Kung; Darren Tomlinson; Margaret A Knowles; Pontus Eriksson; Gottfrid Sjödahl; Jonathan M Salmond; Owen J Sansom; Tomoko Iwata
Journal:  J Pathol       Date:  2018-09-19       Impact factor: 7.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.